From its introduction in 1952 onwards, the clinical use of macrolides has been steadily increasing,
both in human and veterinary medicine. Although initially designed to the treatment of Grampositive
microorganisms, this antimicrobial family has also been used to treat specific Gram-negative
bacteria. Some of them, as azithromycin, are considered in the armamentarium against
Enterobacteriaceae infections. However, the facility that this bacterial genus has to gain or
develop mechanisms of antibiotic resistance may compromise the future usefulness of these antibiotics
to fight against Enterobacteriaceae infections. The present review is focused on the mechanisms
of macrolide resistance, currently described in Enterobacteriaceae.
| Identifer | oai:union.ndltd.org:PERUUPC/oai:repositorioacademico.upc.edu.pe:10757/620710 |
| Date | 27 October 2016 |
| Creators | Gomes, Cláudia, Martínez Puchol, Sandra, Palma, Noemí, Horna, Gertrudis, Ruiz-Roldán, Lidia, Pons, Maria J, Ruiz, Joaquim |
| Contributors | joruiz.trabajo@gmail.com |
| Publisher | Taylor & Francis |
| Source Sets | Universidad Peruana de Ciencias Aplicadas (UPC) |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/article |
| Source | Universidad Peruana de Ciencias Aplicadas (UPC), Repositorio Académico - UPC |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | https://www.tandfonline.com/doi/full/10.3109/1040841X.2015.1136261 |
Page generated in 0.0021 seconds